NF1 Tumor Suppressor Protein and mRNA in Skeletal Tissues of Developing and Adult Normal Mouse and NF1-Deficient Embryos
Open Access
- 1 June 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 19 (6) , 983-989
- https://doi.org/10.1359/jbmr.040130
Abstract
NF1 is a heritable disease with multiple osseous lesions. The expression of the NF1 gene was studied in embryonic and adult rodent skeleton and in NF1‐deficient embryos. The NF1 gene was expressed intensely in the cartilage and the periosteum. Impaired NF1 expression may lead to inappropriate development and dynamics of bones and ultimately to the osseous manifestations of the disease. Introduction: Neurofibromatosis type 1 is caused by mutations in the NF1 gene encoding the Ras GTPase activating protein (Ras‐GAP) neurofibromin. Skeletal ailments such as short stature, kyphoscoliosis, and tibial bowing and pseudarthrosis are common osseous manifestations of NF1. These symptoms are congenital, implying a role for neurofibromin in proper bone growth. However, little is known about its expression in skeletal tissues during their development. Materials and Methods: The expression of the NF1 gene was studied in normal and NF1+/− mouse fetuses at embryonic days 12.5‐15.5 and in skeletal tissues of adult mice and rats. In situ hybridization, immunohistochemistry, and Western blot analysis were used to identify the NF1 gene expression profile. Results: NF1 mRNA and protein were elevated in resting, maturation, and hypertrophic chondrocytes at the growth plate. Parallel studies on NF1+/− embryos showed expression patterns identical to wildtype. The periosteum, including osteoblasts and osteoclasts, and osteocytes of the cortical bone of adult mice were also intensely labeled for NF1 protein and mRNA. Western transfer analysis detected NF1 protein in the respective rat tissues. Phosphorylation of p42 and p44 MAP kinases, the downstream consequence of Ras activation, was elevated in hypertrophic chondrocytes of NF1+/− embryos. Conclusions: The results suggest that neurofibromin may act as a Ras‐GAP in skeletal cells to attenuate Ras transduced growth signals and thus play a role during ossification and dynamics of bone. Loss of NF1 function may therefore lead to dysplastic bone growth, thereby causing the debilitating osseous symptoms of NF1.Keywords
This publication has 31 references indexed in Scilit:
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Review Article : Neurofibromatosis 1: Clinical Review and Exceptions to the RulesJournal of Child Neurology, 2002
- A clinical assessment of neurofibromatosis type 1 (NF1) and segmental NF in northern FinlandJournal of Medical Genetics, 2000
- New Function for NF1 Tumor SuppressorJournal of Investigative Dermatology, 2000
- Congenital Pseudoarthrosis of the RadiusClinical Orthopaedics and Related Research, 1993
- The neurofibromatosis type 1 gene and its protein product, neurofibrominNeuron, 1993
- Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during developmentDevelopmental Dynamics, 1992
- The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytesNeuron, 1992
- Identification and characterization of transcripts from the neurofibromatosis 1 region: The sequence and genomic structure of EVI2 and mapping of other transcriptsGenomics, 1990
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970